| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Juris J Meier, Baptist Gallwitz, Bartholomaeus Kask, Carolyn F Deacon, Jens J Holst, Wolfgang E Schmidt, Michael A Nauc. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. vol 53 Suppl 3. 2005-04-14. PMID:15561915. |
the stimulation of insulin secretion by gip is stronger after its bolus administration than during continuous infusion. |
2005-04-14 |
2023-08-12 |
human |
| Juris J Meier, Baptist Gallwitz, Bartholomaeus Kask, Carolyn F Deacon, Jens J Holst, Wolfgang E Schmidt, Michael A Nauc. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. vol 53 Suppl 3. 2005-04-14. PMID:15561915. |
even though the insulin secretory capacity is generally impaired in patients with type 2 diabetes, the relative sensitivity of insulin secretion to a bolus administration of gip is almost preserved. |
2005-04-14 |
2023-08-12 |
human |
| Juris J Meier, Michael A Nauc. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best practice & research. Clinical endocrinology & metabolism. vol 18. issue 4. 2005-04-08. PMID:15533777. |
later it was found that gip is capable of augmenting glucose-stimulated insulin secretion, and subsequent studies provided evidence that, in humans, the peptide predominantly acts as an incretin hormone. |
2005-04-08 |
2023-08-12 |
human |
| Juris J Meier, Michael A Nauc. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best practice & research. Clinical endocrinology & metabolism. vol 18. issue 4. 2005-04-08. PMID:15533777. |
while gip strongly stimulates insulin release in healthy humans, the peptide has almost completely lost its insulinotropic effect in patients with type 2 diabetes. |
2005-04-08 |
2023-08-12 |
human |
| Bo Ahrén, Thomas E Hughe. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. vol 146. issue 4. 2005-04-08. PMID:15604213. |
in this study, we explored whether dpp-4 inhibition by valine-pyrrolidide (val-pyr; 100 micromol/kg administered through gastric gavage at t = -30 min) affects the insulin and glucose responses to iv glucose (1 g/kg) together with glp-1 (10 nmol/kg), glucose-dependent insulinotropic polypeptide (gip; 10 nmol/kg), pituitary adenylate cyclase-activating polypeptide 38 (pacap38; 1.3 nmol/kg), or gastrin-releasing peptide (grp; 20 nmol/kg) given at t = 0 in anesthetized c57bl/6j mice. |
2005-04-08 |
2023-08-12 |
mouse |
| Bo Ahrén, Thomas E Hughe. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. vol 146. issue 4. 2005-04-08. PMID:15604213. |
it was found that the acute (1-5 min) insulin response to glp-1 was augmented by val-pyr by 80% (4.2 +/- 0.4 vs. 7.6 +/- 0.8 nmol/liter), that to gip by 40% (2.7 +/- 0.3 vs. 3.8 +/- 0.4 nmol/liter), that to pacap38 by 75% (4.6 +/- 0.5 vs. 8.1 +/- 0.6 nmol/liter), and that to grp by 25% (1.8 +/- 0.2 vs. 2.3 +/- 0.3 nmol/liter; all p < 0.05 or less). |
2005-04-08 |
2023-08-12 |
mouse |
| Bo Ahrén, Thomas E Hughe. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. vol 146. issue 4. 2005-04-08. PMID:15604213. |
we conclude that dpp-4 inhibition augments the insulin response not only to glp-1 but also to gip, pacap38, and grp. |
2005-04-08 |
2023-08-12 |
mouse |
| Nigel Irwin, Brian D Green, Victor A Gault, Brett Greer, Patrick Harriott, Clifford J Bailey, Peter R Flatt, Finbarr P M O'Hart. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. Journal of medicinal chemistry. vol 48. issue 4. 2005-04-05. PMID:15715491. |
when administered together with glucose to ob/ob mice, the glycemic excursions were significantly less for both analogues and insulin responses were greater than native gip. |
2005-04-05 |
2023-08-12 |
mouse |
| Lin Li, Burton M Wic. Bombesin and nutrients independently and additively regulate hormone release from GIP/Ins cells. American journal of physiology. Endocrinology and metabolism. vol 288. issue 1. 2005-03-02. PMID:15383372. |
glucose-dependent insulinotropic polypeptide (gip) regulates glucose homeostasis and high-fat diet-induced obesity and insulin resistance. |
2005-03-02 |
2023-08-12 |
Not clear |
| Brian Furman, Nigel Pyne, Peter Flatt, Finbarr O'Hart. Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review. The Journal of pharmacy and pharmacology. vol 56. issue 12. 2005-03-01. PMID:15563754. |
cyclic 3'5'amp is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet beta-cell, where it is formed by the activity of adenylyl cyclase, especially in response to the incretin hormones glp-1 (glucagon-like peptide-1) and gip (glucose-dependent insulinotropic peptide). |
2005-03-01 |
2023-08-12 |
Not clear |
| Nigel Irwin, Victor A Gault, Brian D Green, Brett Greer, Jane T McCluskey, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biological chemistry. vol 385. issue 9. 2005-02-11. PMID:15493880. |
effects of short-term chemical ablation of the gip receptor on insulin secretion, islet morphology and glucose homeostasis in mice. |
2005-02-11 |
2023-08-12 |
mouse |
| Nigel Irwin, Victor A Gault, Brian D Green, Brett Greer, Jane T McCluskey, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biological chemistry. vol 385. issue 9. 2005-02-11. PMID:15493880. |
in this study we have utilized a specific and enzymatically stable gip receptor antagonist, (pro3)gip, to evaluate the contribution of endogenous gip to insulin secretion and glucose homeostasis in mice. |
2005-02-11 |
2023-08-12 |
mouse |
| Nigel Irwin, Victor A Gault, Brian D Green, Brett Greer, Jane T McCluskey, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biological chemistry. vol 385. issue 9. 2005-02-11. PMID:15493880. |
insulin sensitivity of 11-day (pro3)gip treated mice was slightly impaired 60 min post injection compared with controls. |
2005-02-11 |
2023-08-12 |
mouse |
| Nigel Irwin, Victor A Gault, Brian D Green, Brett Greer, Jane T McCluskey, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biological chemistry. vol 385. issue 9. 2005-02-11. PMID:15493880. |
postprandial insulin secretion was not significantly different and no changes in pancreatic insulin content or islet morphology were observed in (pro3)gip treated mice. |
2005-02-11 |
2023-08-12 |
mouse |
| Nigel Irwin, Victor A Gault, Brian D Green, Brett Greer, Jane T McCluskey, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biological chemistry. vol 385. issue 9. 2005-02-11. PMID:15493880. |
these data indicate that ablation of gip signaling causes a readily reversible glucose intolerance without appreciable change of insulin secretion. |
2005-02-11 |
2023-08-12 |
mouse |
| Simon A Hinke, Karine Hellemans, Frans C Schui. Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal. The Journal of physiology. vol 558. issue Pt 2. 2005-01-24. PMID:15181163. |
it is well established that the acute rise in plasma glucose and in the incretin hormones glucose-dependent insulinotropic peptide (gip) and glucagon-like peptide-1 (7-36) amide (glp-1), as occurs during a meal, is of pivotal importance in regulating the minute-to-minute output of insulin from pancreatic beta cells. |
2005-01-24 |
2023-08-12 |
Not clear |
| Lisa I Jepeal, Yoshio Fujitani, Michael O Boylan, Cherrell N Wilson, Christopher V Wright, M Michael Wolf. Cell-specific expression of glucose-dependent-insulinotropic polypeptide is regulated by the transcription factor PDX-1. Endocrinology. vol 146. issue 1. 2005-01-18. PMID:15486225. |
glucose-dependent insulinotropic polypeptide (gip) is a potent stimulator of insulin secretion and comprises an important component of the enteroinsular axis. |
2005-01-18 |
2023-08-12 |
mouse |
| Brian D Green, Victor A Gault, Finbarr P M O'harte, Peter R Flat. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Current pharmaceutical design. vol 10. issue 29. 2004-12-27. PMID:15579061. |
consideration will be given to the effects of n-terminal modification and amino acid substitution of glp-1 and gip either side of the dpp iv cleavage site on (i) susceptibility to enzymatic degradation, (ii) binding to native hormone receptor, (iii) ability to elevate intracellular cyclic amp, (iv) potency as insulin secretagogues, and (v) antihyperglycaemic activity in type 2 diabetes. |
2004-12-27 |
2023-08-12 |
Not clear |
| T Vilsbøll, J J Hols. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia. vol 47. issue 3. 2004-12-22. PMID:14968296. |
this effect, which is called the incretin effect and is estimated to be responsible for 50 to 70% of the insulin response to glucose, is caused mainly by the two intestinal insulin-stimulating hormones, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip). |
2004-12-22 |
2023-08-12 |
Not clear |
| Florian Lippl, Florian Kircher, Johannes Erdmann, Hans-Dieter Allescher, Volker Schusdziarr. Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach. Regulatory peptides. vol 119. issue 1-2. 2004-11-19. PMID:15093702. |
effect of gip, glp-1, insulin and gastrin on ghrelin release in the isolated rat stomach. |
2004-11-19 |
2023-08-12 |
rat |